Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer

Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer

Since 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B...

Full description

Bibliographic Details
Main Authors: Qingzhong Hu, Lina Yin, Rolf W. Hartmann
Format: Article
Language:English
Published: MDPI AG 2013-07-01
Series:International Journal of Molecular Sciences
Subjects:
castration-resistant prostate cancer
Abiraterone
Enzalutamide
Cabazitaxel
Sipuleucel-T
Denosumab
Alpharadin
Online Access:http://www.mdpi.com/1422-0067/14/7/13958

Internet

http://www.mdpi.com/1422-0067/14/7/13958

Similar Items